

Market Release

16 February 2024

Appendix 3Y – Nicholas England

PharmX Technologies Limited (ASX:PHX) (Company)

Chairman Nicholas England purchased PHX securities on market on 12 February 2024. An Appendix 3Y in relation to this share transaction is attached below.

The transaction took place during a closed period during which no trading is permitted under the Company's Securities Trading Policy (**Policy**). Mr England did not obtain the prior approval of the remaining Board members before making the trade. The Company considers the transaction as an inadvertent breach of the Policy by Mr England and believes that the breach does not warrant any disciplinary or remedial action. Mr England has advised the Board of the breach and apologised for his oversight. The Board is satisfied that Mr England's actions were due to a genuine oversight and an honest mistake.

Mr England has undertaken to fully comply with the Policy in respect of any transactions involving the Company's securities in the future. The Company considers that their current arrangements under the Policy are adequate and enforced.

The Company confirms that Mr England was not in possession of any price-sensitive information at the time of the transaction and therefore no insider trading on the part of Mr England occurred.

The Company further notes that:

- a) Mr England only purchased a small number of shares; and
- b) Mr England has not sold any shares in the Company since the transaction.

The Company confirms that it is complying with the Listing Rules, and in particular, Listing Rule 3.1

- ENDS -

This announcement is authorised for release by the Chairman of the Board of PharmX Technologies Limited.

For further information contact:

Tom Culver, Chief Executive Officer
Tom.Culver@pharmx.com.au

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| | |
|-----------------------|--------------------------------|
| Name of entity | PharmX Technologies Ltd |
| ABN | 25 000 091 305 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|----------------------------|-------------------------|
| Name of Director | Philip Nicholas England |
| Date of last notice | 30 November 2020 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|---|
| Direct or indirect interest | Direct and Indirect |
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | Mersault Pty Ltd <The England Super Fund A/C> Mr England is a director of Mersault Pty Ltd |
| Date of change | 12 February 2024 |
| No. of securities held prior to change | 26,853,334 fully paid ordinary shares (Shares) |
| Class | Shares |
| Number acquired | 127,500 Shares |
| Number disposed | Nil |
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | \$0.015 per Share |
| No. of securities held after change | 26,980,834 Shares |

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

| | |
|--|------------------------------|
| Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small> | Purchase of shares on-market |
|--|------------------------------|

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|-----|
| Detail of contract | N/A |
| Nature of interest | N/A |
| Name of registered holder (if issued securities) | N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small> | N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
| Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small> | N/A |
| Interest after change | N/A |

Part 3 – ⁺Closed period

| | |
|---|--|
| Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required? | Yes |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | Prior written clearance was not obtained under the share trading policy. |
| If prior written clearance was provided, on what date was this provided? | N/A |

⁺ See chapter 19 for defined terms.